Skip to content
Dosage GuideResearch Reference

CJC-1295 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for CJC-1295. All information is for educational purposes only.

Quick Answer

CJC-1295 (without DAC / Mod GRF 1-29) is typically administered at 100 mcg per injection, subcutaneously, 1–3 times daily. It is most commonly paired with ipamorelin (100–300 mcg) in a synergistic growth hormone optimization protocol. Timing before sleep or training is commonly used to align with natural GH pulses. No human therapeutic dosing trials have been completed.

→ CJC-1295 Benefits→ CJC-1295 Side Effects→ Full CJC-1295 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 100 mcg per injection, 1–3× daily

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

GH Optimization / Anti-Aging Protocol

100 mcg CJC-1295 + 100–200 mcg ipamorelin1–2× daily (morning and/or pre-bed)
Duration

12–16 weeks

Classic CJC-1295 + ipamorelin stack. Pre-bed dosing aligns with natural nocturnal GH pulse for maximal effect. Fast for at least 2 hours before injecting to avoid blunting GH release by elevated insulin.

Body Composition (Fat Loss + Lean Mass)

100 mcg CJC-1295 + 200–300 mcg ipamorelin2–3× daily
Duration

12–20 weeks

Higher frequency maximizes cumulative GH pulses. Morning, pre-workout, and pre-bed dosing is the common 3× daily protocol.

Post-Injury Recovery

100 mcg CJC-1295 + 200 mcg ipamorelin2× daily
Duration

8–12 weeks

GH elevation supports tissue repair, collagen synthesis, and IGF-1 production. Can be combined with BPC-157 for synergistic healing protocols.

Sleep Improvement

100 mcg CJC-1295 + 100 mcg ipamorelin1× daily, 30 minutes before sleep
Duration

8–12 weeks

Pre-bed dosing specifically targets nocturnal GH release enhancement and slow-wave sleep improvement. Lower doses appropriate for sleep-focused applications.

Timing & Frequency

CJC-1295 without DAC has a half-life of approximately 30 minutes, requiring dosing 2–3× daily for sustained GH elevation throughout the day. Critical: inject on an empty stomach (minimum 2 hours fasted) and avoid eating for 30–60 minutes post-injection. Elevated insulin blunts pituitary response to GHRH stimulation, significantly reducing GH release.

Cycle Guidance

Typical research cycles: 12–16 weeks on, 8–12 weeks off. During off-cycles, the pituitary retains its responsiveness because CJC-1295 (without DAC) preserves pulsatile GH release patterns rather than causing sustained elevation. Longer cycles are used by some researchers (20–24 weeks) given the favorable tolerability profile, though long-term human data is lacking.

Reconstitution Reference

Quick reference for reconstituting CJC-1295. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 2 mg or 5 mg per vial
BAC Water Volume2 mL per 2 mg vial = 1 mg/mL (1,000 mcg/mL)
Concentration & DrawAt 1 mg/mL: 100 mcg dose = 0.1 mL (10 units on a 100-unit insulin syringe)
StorageRefrigerate reconstituted peptide at 2–8°C. Use within 30 days.
StabilityReconstituted: 30 days refrigerated. Lyophilized: 12–24 months room temperature.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard CJC-1295 dosage?
100 mcg per injection is the standard research dose for CJC-1295 without DAC (Mod GRF 1-29). This is typically combined with 100–300 mcg of ipamorelin for synergistic GH release. Doses higher than 100 mcg have not been shown to provide significantly more GH release due to receptor saturation dynamics.
When should CJC-1295 be injected?
The most important timing factor is fasting state — inject on an empty stomach (2+ hours after eating) and wait 30–60 minutes before eating again. Popular timing: morning (fasted), 30–60 minutes pre-workout, and/or 30 minutes before sleep. Pre-bed dosing aligns with the body's natural nocturnal GH pulse, which is the largest daily pulse in most adults.
How many units do I draw for 100 mcg of CJC-1295?
This depends on your reconstitution concentration. Most common: add 2 mL BAC water to a 2 mg vial = 1,000 mcg/mL. For 100 mcg: draw to the 10-unit mark on a 100-unit insulin syringe. Use our Reconstitution Calculator (/tools/reconstitution-calculator) for any combination.
Should I use CJC-1295 with or without DAC?
CJC-1295 without DAC (Mod GRF 1-29) is generally preferred for research purposes because it maintains a physiological pulsatile GH release pattern with a shorter half-life (~30 minutes). CJC-1295 with DAC has a much longer half-life (days) and causes sustained GH elevation, which may suppress natural pulsatility. The without-DAC version is considered more physiological.
Can CJC-1295 be used alone without ipamorelin?
Yes, but the combination is significantly more effective. CJC-1295 alone increases GHRH signaling (amplifying GH pulses), while ipamorelin adds a separate GH secretagogue signal via the ghrelin receptor. Combined, they produce a synergistic GH response — often 2–4× more than either alone. The stack is so commonly used that CJC-1295 + ipamorelin is often called the "gold standard" GH optimization combination.
How long does it take for CJC-1295 to work?
GH levels rise within 15–30 minutes of injection, peaking around 30–60 minutes. Downstream effects (improved sleep, body composition changes, recovery improvements) typically require 4–8 weeks of consistent use to become subjectively noticeable. IGF-1 levels — a longer-lasting marker of GH activity — usually show measurable increases after 2–4 weeks of consistent dosing.

References

  1. 1
    A single dose of the long acting GH secretagogue CJC-1295 stimulates GH secretion for days in normal young adults(2006)PubMed ↗
  2. 2
    Pharmacokinetics and pharmacodynamics of GRF analogs in rhesus macaques(2003)PubMed ↗
  3. 3
    Growth hormone-releasing hormone: clinical studies and therapeutic aspects(1998)PubMed ↗
  4. 4
    Growth hormone secretagogues: spectrum of physiological activities(1998)PubMed ↗
  5. 5
    Growth hormone-releasing hormone — analogues and applications(1999)PubMed ↗

Last updated: 2026-02-26